Brief: Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA
22/07/2026 23:01
BRIEF-Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA July 22 (Reuters) - Revolution Medicines Inc RVMD.O:
REVOLUTION MEDICINES’ NEW DRUG APPLICATION FOR DARAXONRASIB ACCEPTED FOR REVIEW BY U.S. FDA FOR PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER
Source text: ID:nGNX9QmXLD
Further company coverage: RVMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns